Pulmatrix Inc
Closed
1.31 -0.76
Overview
Share price change
24h
Min
1.23
Max
1.33
Income | -244K -1.2M |
|---|---|
EPS | -0.254 |
Employees | 2 |
EBITDA | -364K -1.3M |
Market Cap | 37K 4.6M |
|---|---|
Previous open | 2.07 |
Previous close | 1.31 |
Pulmatrix Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pulmatrix Inc Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pulmatrix Inc
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
